TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial

~ Phase 1 Dosing of Voriconazole Inhalation Powder up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis (IPA) ~ Phase 2 studies to commence, assessing the efficacy of the dry powder formulation for the treatment of IPA ~ Company is investigating potential treatment or prevention of COVID-19 Associated Pulmonary Aspergillosis (CAPA) and other pulmonary fungal infections

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here